Gag突变在瑞士HIV队列研究中对PI耐药的作用:旁观者还是贡献者?
本研究基于瑞士HIV队列研究2004-12年血浆样本,分析经PI治疗与未治疗患者的Gag和蛋白酶突变谱。发现超过半数PI经治患者携带至少一种已知Gag突变,17.9%(66/369)携带经体外诱变证实PI耐药的Gag突变,并识别出多个与PI暴露和治疗失败相关的新Gag突变。结论提示Gag突变与PI暴露相关,可能低估PI耐药水平。
要点
- 超过半数PI经治患者携带至少一种已知Gag突变。
- 17.9%(66/369)携带经体外诱变证实PI耐药的Gag突变。
- 识别出多个与PI暴露和治疗失败相关的新Gag突变。
核心结论
- Gag突变(已知和新发现)与PI暴露相关,可能具有临床意义,因潜在PI耐药水平可能被低估。
研究设计与样本
- 基于瑞士HIV队列研究2004-12年血浆样本,配对蛋白酶和Gag C端序列与治疗史,比较PI经治与初治患者的突变 prevalence,并用随机树混合模型建模突变累积路径。
主要发现
- 超过半数PI经治患者携带至少一种已知Gag突变。
- 17.9%(66/369)携带至少一种经体外诱变证实PI耐药的Gag突变。
- 识别出多个与PI暴露和治疗失败相关的新Gag突变。
临床怎么用
- 当前基因型算法仅考虑蛋白酶基因评估PI耐药,可能低估耐药水平,临床应关注Gag突变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HIV Gag mutations have been reported to confer PI drug resistance. However, clinical implications are still controversial and most current genotyping algorithms consider solely the protease gene for assessing PI resistance. OBJECTIVES: Our goal was to describe for HIV infections in Switzerland the potential role of the C-terminus of Gag (NC-p6) in PI resistance. We aimed to characterize resistance-relevant mutational patterns in Gag and protease and their possible interactions. METHODS: Resistance information on plasma samples from 2004-12 was collected for patients treated by two diagnostic centres of the Swiss HIV Cohort Study. Sequence information on protease and the C-terminal Gag region was paired with the corresponding patient treatment history. The prevalence of Gag and protease mutations was analysed for PI treatment-experienced patients versus PI treatment-naive patients. In addition, we modelled multiple paths of an assumed ordered accumulation of genetic changes using random tree mixture models. RESULTS: More than half of all PI treatment-experienced patients in our sample set carried HIV variants with at least one of the known Gag mutations, and 17.9% (66/369) carried at least one Gag mutation for which a phenotypic proof of PI resistance by in vitro mutagenesis has been reported. We were able to identify several novel Gag mutations that are associated with PI exposure and therapy failure. CONCLUSIONS: Our analysis confirmed the association of Gag mutations, well known and new, with PI exposure. This could have clinical implications, since the level of potential PI drug resistance might be underestimated.
引用
- Kletenkov K, Hoffmann D, Böni J, et al. Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors? J Antimicrob Chemother. 2017. PMID: 27999036. doi:10.1093/jac/dkw493
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。